A pilot study of MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in small-cell lung cancer
1998

MVP Chemotherapy in Small-Cell Lung Cancer

Sample size: 50 publication Evidence: moderate

Author Information

Author(s): TF Hickish, IE Smith, MC Nicolson, S Ashley, K Priest, L Spencer, A Norman, G Middleton, MER O'Brien

Primary Institution: Royal Marsden Hospital

Hypothesis

Is MVP chemotherapy effective in treating small-cell lung cancer?

Conclusion

MVP chemotherapy is effective in treating small-cell lung cancer with low toxicity.

Supporting Evidence

  • 79% overall response rate with 17% complete response and 62% partial response.
  • Median survival was 10 months for limited disease patients and 6 months for extensive disease patients.
  • Quality of life improved significantly in emotional and cognitive functioning.

Takeaway

Doctors tested a new medicine called MVP on patients with lung cancer, and it helped many of them feel better without making them very sick.

Methodology

Fifty previously untreated patients with small-cell lung cancer received MVP chemotherapy and were monitored for response and toxicity.

Limitations

The study had a small sample size and was a pilot trial.

Participant Demographics

33 men and 17 women, median age 66 years (range 46-83 years).

Statistical Information

P-Value

p<0.05

Confidence Interval

95% CI 78-96%

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication